a modelled economic evaluation comparing atomoxetine with methylphenidate in the treatment of children with attention-deficithyperactivity disorder in spain经济评价模型比较以和哌醋甲酯治疗儿童attention-deficithyperactivity障碍在西班牙.pdfVIP

下载本文档

1
0
约8.69万字
约 13页
2017-09-05 发布于上海
举报
版权申诉

a modelled economic evaluation comparing atomoxetine with methylphenidate in the treatment of children with attention-deficithyperactivity disorder in spain经济评价模型比较以和哌醋甲酯治疗儿童attention-deficithyperactivity障碍在西班牙.pdf

1、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。。
2、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
4、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
5、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
6、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
7、VIP文档为合作方或网友上传，每下载1次，网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档

a modelled economic evaluation comparing atomoxetine with methylphenidate in the treatment of children with attention-deficithyperactivity disorder in spain经济评价模型比较以和哌醋甲酯治疗儿童attention-deficithyperactivity障碍在西班牙

BMC Psychiatry BioMed Central Research article Open Access A modelled economic evaluation comparing atomoxetine with methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder in Spain 1,2 3 2 Jihyung Hong* , Tatiana Dilla and Jorge Arellano Address: 1LSE Health, London School of Economics, London, UK, 2Eli Lilly and Company, Windlesham, UK and 3Eli Lilly and Company, S.A, Alcobendas (Madrid), Spain Email: Jihyung Hong* - j.hong@lse.ac.uk; Tatiana Dilla - dilla_tatiana@; Jorge Arellano - arellano_jorge@ * Corresponding author Published: 14 April 2009 Received: 30 August 2008 Accepted: 14 April 2009 BMC Psychiatry 2009, 9:15 doi:10.1186/1471-244X-9-15 This article is available from: /1471-244X/9/15 © 2009 Hong et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Abstract Background: Attention Deficit/Hyperactivity Disorder (ADHD) is a neurobehavioural disorder, affecting 3–6% of school age children and adolescents in Spain. Methylphenidate (MPH), a mild stimulant, had long been the only approved medication available for ADHD children in Spain. Atomoxetine is a non-stimulant alternative in the treatment of ADHD with once-a-day or